New Monoclonal Antibody Approved to Treat Multiple Myeloma

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 116, Nº. 3, 2016, págs. 22-22
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * Elotuzumab (Empliciti) is a new monoclonal antibody approved to treat multiple myeloma in combination with lenalidomide (Revlimid) and dexamethasone.

    * Use is restricted to patients who have already received one to three drug therapies to treat the condition.

    * Elotuzumab commonly produces infusion reactions, and premedication is necessary. Patients may also develop second primary malignancies or hepatotoxicity. Response to the drug can be difficult to measure.